Abstract
Multiple myeloma is a plasma cell malignancy that manifests with bone lesions, anemia, hypercalcemia and renal dysfunction. With the advent of proteasome inhibitors and immunomodulatory agents, the response rates have significantly improved leading to a higher rates of complete response and stringent complete response. However, patients still relapse over a period of time even after consolidation of response by autologous stem cell trasplantation. There is therefore a need to assess the medullary and extramedullary compartments of residual plasma cell burden to identify patients who will require further therapy. Assessing minimal residual disease in the intramedullary compartment is best done by multiprameter flow cytometry. With standardised 8-10 colour flow cytometry, detection of upto 0.001% neoplastic plasma cells is now possible. This chapter will discuss the details of intramedullary minimal residual disease detection in multiple myeloma.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Rajkumar SV, Dimopoulos MA, Palumbo A, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15:e538–48.
Moreau P, Attal M, Facon T. Frontline therapy of multiple myeloma. Blood. 2015;125:3076–84.
Rajkumar SV. Multiple myeloma: 2014 update on diagnosis, risk-stratification, and management. Am J Hematol. 2014;89:998–1009.
Howlader N, Noone A, Krapcho M, et al. Seer Cancer Statistics Review, 1975–2009 (Vintage 2009 populations). Bethesda: National Cancer Institute; 2012.
Landgren O, Weiss BM. Patterns of monoclonal gammopathy of undetermined significance and multiple myeloma in various ethnic/racial groups: support for genetic factors in pathogenesis. Leukemia. 2009;23:1691–7.
Kristinsson SY, Anderson WF, Landgren O. Improved long-term survival in multiple myeloma up to the age of 80 years. Leukemia. 2014;28:1346–8.
Kumar SK, Dispenzieri A, Lacy MQ, et al. Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. Leukemia. 2014;28:1122–8.
Kumar SK, Rajkumar SV, Dispenzieri A, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood. 2008;111:2516–20.
Singhal S, Mehta J, Desikan R, et al. Antitumor activity of thalidomide in refractory multiple myeloma [see comments]. N Engl J Med. 1999;341:1565–71.
Richardson PG, Blood E, Mitsiades CS, et al. A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood. 2006;108:3458–64.
Rajkumar SV, Hayman SR, Lacy MQ, et al. Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma. Blood. 2005;106:4050–3.
Richardson PG, Sonneveld P, Schuster MW, et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med. 2005;352:2487–98.
Siegel DS, Martin T, Wang M, et al. A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma. Blood. 2012;120(14):2817–25. https://doi.org/10.1182/blood-2012-05-425934.
Lonial S, Brendan M, Usmani SZ, et al. Single-agent daratumumab in heavily pretreated patients with multiple myeloma (Sirius): an open-label, international, multicentre phase 2 trial. Lancet. 2016;387:1551–60.
Lonial S, Dimopoulos M, Palumbo A, et al. elotuzumab therapy for relapsed or refractory multiple myeloma. N Engl J Med. 2015;373:621–31.
Moreau P, Masszi T, Grzasko N, et al. Ixazomib, an investigational oral proteasome inhibitor (PI), in combination with lenalidomide and dexamethasone (IRd), significantly extends progression-free survival (PFS) for patients (Pts) with relapsed and/or refractory multiple myeloma (RRMM): the phase 3 tourmaline-MM1 study (NCT01564537). Blood. 2015;126. Abstract 727.
Landgren O, Owen RG. Better therapy requires better response evaluation: paving the way for minimal residual disease testing for every myeloma patient. Cytometry B Clin Cytom. 2016;90:14–20.
Mailankody S, Korde N, Lesokhin AM, et al. Minimal residual disease in multiple myeloma: bringing the bench to the bedside. Nat Rev ClinOncol. 2015;12:286–95.
Attal M, Lauwers-Cances V, Marit G, et al. Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. N Engl J Med. 2012;366:1782–91.
McCarthy PL, Owzar K, Hofmeister CC, et al. Lenalidomide after stem-cell transplantation for multiple myeloma. N Engl J Med. 2012;366:1770–81.
Jakubowiak AJ, Dytfeld D, Griffith KA, et al. A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma. Blood. 2012;120:1801–9.
Kumar S, Flinn I, Richardson PG, et al. Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma. Blood. 2012;119:4375–82.
Attal M, Harousseau JL, Stoppa AM, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med. 1996;335:91–7.
Child JA, Morgan GJ, Davies FE, et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med. 2003;348:1875–83.
Durie BG, Harousseau JL, Miguel JS, et al. International uniform response criteria for multiple myeloma. Leukemia. 2006;20:1467–73.
Rajkumar SV, Harousseau JL, Durie B, et al. Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. Blood. 2011;117:4691–5.
Tatsas AD, Jagasia MH, Chen H, McCurley TL. Monitoring residual myeloma: high-resolution serum/urine electrophoresis or marrow biopsy with immunohistochemical analysis? Am J ClinPathol. 2010;134:139–44.
Chee CE, Kumar S, Larson DR, et al. The importance of bone marrow examination in determining complete response to therapy in patients with multiple myeloma. Blood. 2009;114:2617–8.
Rawstron AC, Davies FE, DasGupta R, et al. Flow cytometric disease monitoring in multiple myeloma: the relationship between normal and neoplastic plasma cells predicts outcome after transplantation. Blood. 2002;100:3095–100.
Paiva B, Vidriales MB, Cervero J, et al. Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation. Blood. 2008;112:4017–23.
Korde N, Roschewski M, Zingone A, et al. Treatment with carfilzomib-lenalidomide-dexamethasone with lenalidomide extension in patients with smoldering or newly diagnosed multiple myeloma. JAMA Oncol. 2015;1:746–54.
Mateos MV, Oriol A, Martinez-Lopez J, et al. GEM2005 trial update comparing VMP/VTP as induction in elderly multiple myeloma patients: do we still need alkylators? Blood. 2014;124:1887–93.
Paiva B, Martinez-Lopez J, Vidriales MB, et al. Comparison of immunofixation, serum free light chain, and immunophenotyping for response evaluation and prognostication in multiple myeloma. J ClinOncol. 2011;29:1627–33.
Rawstron AC, Child JA, de Tute RM, et al. Minimal residual disease assessed by multiparameter flow cytometry in multiple myeloma: impact on outcome in the Medical Research Council Myeloma IX Study. J ClinOncol. 2013;31:2540–7.
Paiva B, Gutiérrez NC, Rosiñol L, et al. High-risk cytogenetics and persistent minimal residual disease by multiparameter flow cytometry predict unsustained complete response after autologous stem cell transplantation in multiple myeloma. Blood. 2012;119:687–91.
Mathis S, Chapuis N, Borgeot J, et al. Comparison of cross-platform flow cytometry minima residual disease evaluation in multiple myeloma using a common antibody combination and analysis strategy. Cytometry B Clin Cytom. 2015;88:101–9.
Silvennoinen R, Kairisto V, Pelliniemi TT, et al. Assessment of molecular remission rate after bortezomib plus dexamethasone induction treatment and autologous stem cell transplantation in newly diagnosed multiple myeloma patients. Br J Haematol. 2013;160:561–4.
Martinelli G, Terragna C, Zamagni E, et al. Molecular remission after allogeneic or autologous transplantation of hematopoietic stem cells for multiple myeloma. J Clin Oncol. 2000;18:2273–81.
Sarasquete ME, Garcıa-Sanz R, Gonzalez D, et al. Minimal residual disease monitoring in multiple myeloma: a comparison between allelic-specific oligonucleotide real-time quantitative polymerase chain reaction and flow cytometry. Haematologica. 2005;90:1365–72.
Puig N, Sarasquete ME, Balanzategui A, et al. Critical evaluation of ASORQ-PCR for minimal residual disease evaluation in multiple myeloma. A comparative analysis with flow cytometry. Leukemia. 2014;28:391–7.
Moreau P, Attal M, Caillot D, et al. Prospective evaluation of magnetic resonance imaging and [18F]fluorodeoxyglucose positron emission tomography-computed tomography at diagnosis and before maintenance therapy in symptomatic patients with multiple myeloma included in the IFM/DFCI 2009 trial: results of the IMAJEM study. J Clin Oncol. 2017;35:2911–8.
Rasche L, Schinke C, Alapat D, et al. Functional imaging detects residual disease in MRD-negative multiple myeloma patients who subsequently relapse. Blood. 2017;130:4510.
Fernandez RA, Cedena MT, Rios R, et al. Maintenance treatment with lenalidomide for multiple myeloma increases the proportion of MRD negative (flow-/PET-CT-) patients. Blood. 2017;130:3098.
Zamagni E, Nanni C, Mancuso K, et al. PET/CT improves the definition of complete response and allows to detect otherwise unidentifiable skeletal progression in multiple myeloma. Clin Cancer Res. 2015;21(19):4384–90.
de Tute RM, Jack AS, Child J, et al. A single-tube six-colour flow cytometry screening assay for the detection of minimal residual disease in myeloma. Leukemia. 2007;21:2046–9.
Gupta R, Bhaskar A, Kumar L, Sharma A, Jain P. Flow cytometric immunophenotyping and minimal residual disease analysis in multiple myeloma. Am J Clin Pathol. 2009;132:728–32.
Paiva B, Chandia M, Puig N, et al. The prognostic value of multiparameter flow cytometry minimal residual disease assessment in relapse multiple myeloma. Haematologica. 2015;100:e53–5.
Robillard N, Bene MC, Moreau P, Wuilleme S. A single-tube multi-parameter seven-colour flow cytometry strategy for the detection of malignant plasma cells in multiple myeloma. Blood Cancer J. 2013;3:e134.
Roussel M, Lauwers-Cances V, Robillard N, et al. Front-line transplantation program with lenalidomide, bortezomib, and dexamethasone combination as induction and consolidation followed by lenalidomide maintenance in patients with multiple myeloma: a phase II study by the Intergroupe Francophone du Myelome. J Clin Oncol. 2014;32:2712–7.
Flores-Montero J, Sanoja-Flores L, Paiva B, et al. Next generation flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma. Leukemia. 2017;31:2094–103.
Domingo E, Moreno C, Sanchez-Ibarrola A, et al. Enhanced sensitivity of flow cytometry for routine assessment of minimal residual disease. Haematologica. 2010;95:691–2.
Roshal R, Flores-Montero JA, Gao Q, et al. MRD detection in multiple myeloma: comparison between MSKCC 10-color single-tube and EuroFlow 8-color 2-tube methods. Blood Adv. 2017;1(12):728–32.
Royston DY, Gao Q, Nguyen N, et al. Single-tube 10-fluorochrome analysis for efficient flow cytometric evaluation of minimal residual disease in plasma cell myeloma. Am J Clin Pathol. 2016;146:41–9.
Rawstron A, Gregory WM, de Tute RM, et al. Minimal residual disease in myeloma by flow cytometry: independent prediction of survival benefit per log reduction. Blood. 2015;125:1932–5.
Munshi NC, Avet-Loiseau H, Rawstron A, et al. Association of minimal residual disease with superior survival outcomes in patients with multiple myeloma a meta-analysis. JAMA Oncol. 2017;3:28–35.
Landgren O, Devlin S, Boulad M, Mailankody S. Role of MRD status in relation to clinical outcomes in newly diagnosed multiple myeloma patients: a meta-analysis. Bone Marrow Transplant. 2016;51:1565–8.
Gromley NJ, Farrell AT, Pazdur R. Minimal residual disease as a potential surrogate end point—lingering questions. JAMA Oncol. 2017;3:18–20.
http://www.cytognos.com/index.php/euroflow/minimal-residual-disease-panels/1440-multiple-myeloma-mm-mrd-kits. Accessed 26 Dec 2017.
Martinez-Lopez J, Lahuerta JJ, Pepin F, et al. Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma. Blood. 2014;123:3073–9.
Avet-Loiseau H. Minimal residual disease by next-generation sequencing: pros and cons. Am Soc Clin Oncol Educ Book. 2016;35:e425–30.
Kumar S, Paiva B, Anderson KC, et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17:e328–46.
Paiva B, van Dongen JJ, Orfao A. New criteria for response assessment role of minimal residual disease in multiple myeloma. Blood. 2015;125:3059–68.
Rawstron AC, Orfao A, Beksac M, et al. Report of the European Myeloma Network on multiparametric flow-cytometry in multiple myeloma and related disorders. Haematologica. 2008;93:431–8.
Wood BL. Principles of minimal residual disease detection for hematopoietic neoplasms by flow cytometry. Cytometry B Clin Cytom. 2016;90B:47–53.
Rawstron AC, Pavia B, Stetler-Stevenson M. Assessment of minimal residual disease in myeloma and the need for a consensus approach. Cytometry B Clin Cytom. 2016;90B:21–5.
Stetler-Stevenson M, Paiva B, Stoolman L, et al. Consensus guidelines for myeloma minimal residual disease sample staining and data acquisition. Cytometry B Clin Cytom. 2016;90B:26–30.
Arroz M, Came N, Lin P, et al. Consensus guidelines on plasma cell myeloma minimal residual disease analysis and reporting. Cytometry B Clin Cytom. 2016;90B:31–9.
Oldaker TA, Wallace PK, Barnett D. Flow cytometry quality requirements for monitoring of minimal disease in plasma cell myeloma. Cytometry B Clin Cytom. 2016;90B:40–6.
Rawstron AC, de Tute RM, Haughton J, Owen RG. Measuring disease levels in myeloma using flow cytometry in combination with other laboratory techniques: lessons from the past 20 years at the Leeds Haematological Malignancy Diagnostic Service. Cytometry B Clin Cytom. 2016;90B:54–60.
Flores-Montero J, de Tute R, Paiva B, et al. Immunophenotype of normal vs. myeloma plasma cells: toward antibody panel specifications for MRD detection in multiple myeloma. Cytometry B Clin Cytom. 2016;90B:61–72.
Gormley NJ, Turley DM, Dickey JS, et al. Regulatory perspective on minimal residual disease flow cytometry testing in multiple myeloma. Cytometry B Clin Cytom. 2016;90B:73–80.
Vittorio Emanuele M, Elona S, Milena G, et al. Multiple myeloma: new surface antigens for the characterization of plasma cells in the era of novel agents. Cytometry B Clin Cytom. 2016;90B:81–90.
Pojero F, Flores-Montero J, Sanoja L, et al. Utility of CD54, CD229, and CD319 for the identification of plasma cells in patients with clonal plasma cell diseases. Cytometry B Clin Cytom. 2016;90B:91–100.
Barnett DSI, Wilson GA, Granger V, Reilly JT. Determination of leucocyte antibody binding capacity (ABC): the need for standardization. Clin Lab Haematol. 1998;20:155–64.
Terstappen LW, Johnsen S, Segers-Nolten IM, Loken MR. Identification and characterization of plasma cells in normal human bone marrow by high-resolution flow cytometry. Blood. 1990;76:1739–47.
Wijdenes J, Vooijs WC, Clement C, et al. A plasmocyte selective monoclonal antibody (B-B4) recognizes syndecan-1. Br J Haematol. 1996;94:318–23.
Darzalex (daratumumab) injection [prescribing information]. Horsham: Janssen Biotech, Inc; 2015.
Lin P, Owens R, Tricot G, Wilson CS. Flow cytometric immunophenotypic analysis of 306 cases of multiple myeloma. Am J Clin Pathol. 2004;121:482–8.
Almeida J, Orfao A, Ocqueteau M, et al. High-sensitive immunophenotyping and DNA ploidy studies for the investigation of minimal residual disease in multiple myeloma. Br J Haematol. 1999;107:121–31.
Mateo G, Montalban MA, Vidriales M, et al. Prognostic value of immunophenotyping in multiple myeloma: a study by the PETHEMA/GEM cooperative study groups on patients uniformly treated with high-dose therapy. J Clin Oncol. 2008;26:2737–44.
Tembhare P, Yuan CM, Venzon D, et al. Flow cytometric differentiation of abnormal and normal plasma cells in the bone marrow in patients with multiple myeloma and its precursor diseases. Leuk Res. 2014;38:371–6.
Robillard N, Wuilleme S, Moreau P, Bene MC. Immunophenotype o fnormal and myelomatous plasma-cell subsets. Front Immunol. 2014;5:137.
Cannizzo E, Bellio E, Sohani AR, et al. Multiparameter immuno-phenotyping by flow cytometry in multiple myeloma: the diagnostic utility of defining ranges of normal antigenic expression in comparison to histology. Cytometry B Clin Cytom. 2010;78:231–8.
vanDongen JJM, Lhermitte L, Bottcher S, et al. EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes. Leukemia. 2012;26:1908–75.
Paiva B, Gutierrez NC, Chen X, et al. Clinical significance of CD81 expression by clonal plasma cells in high-risk smoldering and symptomatic multiple myeloma patients. Leukemia. 2012;26:1862–9.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Nature Singapore Pte Ltd.
About this chapter
Cite this chapter
Dass, J., Kotwal, J. (2019). Minimal Residual Disease Assessment in Myeloma. In: Saxena, R., Pati, H. (eds) Hematopathology. Springer, Singapore. https://doi.org/10.1007/978-981-13-7713-6_14
Download citation
DOI: https://doi.org/10.1007/978-981-13-7713-6_14
Published:
Publisher Name: Springer, Singapore
Print ISBN: 978-981-13-7712-9
Online ISBN: 978-981-13-7713-6
eBook Packages: MedicineMedicine (R0)